Thermo Fisher Scientific discovered novel biomakers such as B·R·A·H·M·S PlGF plus KRYPTOR and B·R·A·H·M·S sFlt-1 KRYPTOR.
These biomarkers are the first and currently the only immunoassays available for assessing the risk and managing preeclampsia, a serious complication during pregnancy.
These new assays are designed to be used as part of a comprehensive approach to assess the risk of pregnant women who have been hospitalised for hypertensive disorders of pregnancy.
These assays are intended to provide additional information that can aid in determining if these women are at risk of developing preeclampsia with severe features within the next two weeks.
The B•R•A•H•M•S KRYPTOR compact PLUS clinical chemistry analyser is specifically designed to accommodate the new assays. By using the advanced TRACE technology, this analyser is capable of providing results in less than 30 minutes, ensuring rapid turnaround time for diagnostic testing.
Preeclampsia is indeed a serious condition that can pose significant risks to both the mother and the baby during pregnancy and in the postpartum period. It has emerged as a leading cause of maternal and foetal mortality and morbidity on a global scale.
The U.S. Food and Drug Administration (FDA) has recently granted clearance to the B•R•A•H•M•S PlGF plus KRYPTOR and B•R•A•H•M•S sFlt-1 KRYPTOR novel biomarkers.
